Atrial Fibrillation Clinical Trial
— RCR-OACOfficial title:
Retrospective Medical Chart Review Study for Atrial Fibrillation Patents Treated With Oral Anticoagulant
Verified date | May 2022 |
Source | Bristol-Myers Squibb |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study is to compare the risk of major bleeding among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating treatment
Status | Completed |
Enrollment | 12354 |
Est. completion date | December 25, 2020 |
Est. primary completion date | December 25, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - Individuals greater than or equal to 20 years old as of the index date - At least 1 diagnosis of NVAF prior to or on index date, identified by any medical records - Newly treated with warfarin or apixaban between 01-Jan-2011 to 31-Dec-2016. The first warfarin or apixaban prescription date during the identification period will be designated as the index date Exclusion Criteria: - Patient's medical records indicating pregnancy during the follow-up period - Patient's medical records indicating taking warfarin, apixaban, dabigatran, rivaroxaban, or edoxaban during the 6-months prior to the index date - Had > 1 OAC prescription in the patient's medical records on the index date Other protocol defined inclusion/exclusion criteria could apply |
Country | Name | City | State |
---|---|---|---|
Japan | Local Institution | Minato-ku | Tokyo |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb | Pfizer |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of major bleeding among oral anticoagulant (OAC) initiators | Maximum 3 years | ||
Secondary | Incidence of thromboembolic events | Maximum 3 years | ||
Secondary | Incidence of stoke/SE (secondary event) among OAC initiators | Maximum 3 years | ||
Secondary | Incidence of major bleeding and stoke/SE (secondary event) among OAC initiators stratified by CCr | CCr creatinine clearance (< 50ml/min and > 50ml/min) | Maximum 3 years | |
Secondary | Incidence of cardiovascular/all cause death among OAC initiators | Maximum 3 years | ||
Secondary | Incidence of myocardial infarction among OAC initiators | Maximum 3 years | ||
Secondary | Incidence of major adverse cardiac event among OAC initiators | Maximum 3 years | ||
Secondary | Incidence of cardiovascular/all cause death among OAC initiators stratified by CCr (creatinine clearance rate) | CCr (< 50ml/min and > 50ml/min) | Maximum 3 years | |
Secondary | Incidence of myocardial infarction among OAC initiators stratified by CCr | CCr (< 50ml/min and > 50ml/min) | Maximum 3 years | |
Secondary | Incidence of major adverse cardiac event among OAC initiators stratified by CCr | CCr (< 50ml/min and > 50ml/min) | Maximum 3 years | |
Secondary | Distribution of clinical characteristics among OAC initiators | Clinical characteristics will be summarized using descriptive statistics | Maximum 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |